Treatment of Candida infection: a view from the trenches!
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: To provide an overview of the treatment of Candida infections from the perspective of the infectious disease clinician in the community. An insight is given into relevant issues as they apply to clinical practice. As community hospitals strive to provide state-of-the-art medical care to critically ill patients, effective infection control programs and the infectious disease consultation availability become indispensable. RECENT FINDINGS: Candida infections rank as the fourth most common cause of nosocomial bloodstream infections. Although C. albicans remains the most common pathogen, emerging trends in invasive candidiasis are notable for a dramatic increase in infections due to non-albicans Candida species, reflecting changes in clinical practice. These trends affect our practice because infections with non-albicans species raise concerns for inherent decreased antifungal susceptibility, ultimately impacting our preventive, empirical and therapeutic approaches. It seems inevitable for most acutely ill patients today to be admitted to the intensive care unit, thus increasing their risk for nosocomial infections. In addition, cost containment efforts may force patients receiving intravenous therapy into less supervised environments, potentially increasing their risk for candidemia. SUMMARY: Potentially fatal Candida infections are commonplace in seriously ill hospitalized patients. The infectious disease physician is challenged to develop expertise in using the newly introduced antifungal agents, applying evidence-based guidelines developed from quality randomized clinical trials. The infectious disease specialist is called to play a multidisciplinary role formulating infection control policies, developing drug formularies, educating the staff and treating the sickest patients. Infection surveillance in local communities coupled with available antifungal agents may improve our management of Candida infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., & Hollis, R. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.852-856.2002 · Cited by 331
Macphail, G. L. P., Taylor, G. D., Buchanan‐Chell, M., Ross, C., Wilson, S., & Kureishi, A. (2002) · Mycoses · doi:10.1046/j.1439-0507.2002.00741.x · Cited by 119
Joseph Baran Jr, B. M. (2001) · Scandinavian Journal of Infectious Diseases · doi:10.1080/003655401750065544 · Cited by 70
Cited by
Insights into Candida tropicalis nosocomial infections and virulence factors
Negri, M., Silva, S., Henriques, M., & Oliveira, R. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1455-z · Cited by 132
“Methods such as polymerase chain reaction (PCR) assay [47, 49, 50] and realtime PCR assays [45, 51], described in Table 2, have been successfully used to identify C.”
MethodIdentification of the Candida albicans Cap1p Regulon
Znaidi, S., Barker, K. S., Weber, S., Alarco, A.-M., Liu, T. T., Boucher, G., Rogers, P. D., & Raymond, M. (2009) · Eukaryotic Cell · doi:10.1128/ec.00002-09 · Cited by 115
Exposure of Candida albicans β (1,3)-glucan is promoted by activation of the Cek1 pathway
Chen, T., Jackson, J. W., Tams, R. N., Davis, S. E., Sparer, T. E., & Reynolds, T. B. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007892 · Cited by 56
Chen, Y.-L., Kauffman, S., & Reynolds, T. B. (2008) · Infection and Immunity · doi:10.1128/iai.01514-07 · Cited by 47
“albicans is the species most commonly isolated from patients with these infections (4).”
Background
Metadata
- Authors
- Bustamante, C. I.
- Venue
- Current Opinion in Infectious Diseases
- Published
- 2005-12
- Volume
- 18
- Issue
- 6
- Pages
- 490-495
- ISSN
- 0951-7375 (ISSN-L)
- OpenAlex
- W1974848894
- Cited by
- 51
- References
- 10
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Candida infection: a view from the trenches! https://app.cochat.ai/papers/10.1097/01.qco.0000191516.43792.61
- The paper
- Bustamante, C. I. (2005). Treatment of Candida infection: a view from the trenches! Current Opinion in Infectious Diseases. https://doi.org/10.1097/01.qco.0000191516.43792.61
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.